Scientific insights: Why China Now Owns the Late-Stage IL-4R Pipeline
Of the Eight IL-4Rα Assets in Phase III Right Now, Seven Are Chinese. The Eighth Is Licensed to China Too.
IL-4Rα is the mechanism behind Dupixent, one of the best-selling drugs in the world, used to treat atopic dermatitis (eczema), asthma, and other type 2 inflammatory diseases. It’s about as validated as a drug target gets, which is exactly why the current picture is worth a closer look.
The pattern
We ran a landscape on IL-4Rα in VibeOne, and this is what came back immediately: of the eight IL-4Rα assets currently in Phase III, seven are run by Chinese companies. The eighth, Connect Biopharma’s rademikibart, is US-headquartered, but it’s licensed to Simcere for development and commercialization across Greater China. Eight for eight, by ownership or by rights.
The Phase III bench: TQH2722 (Chia Tai Tianqing), telikibart/GR1802 (Genrix), manfidokimab/AK120 (Akeso), SSGJ-611 (Sunshine Guojian/3SBio), SHR-1819 (Hengrui), QX005N (Qyuns/Huadong), and QL2108 (Qilu).
Ahead of that group, two assets have already cleared Phase III entirely: MG-K10 (Mabgeek/CMS) is under NDA review in China, and stapokibart (KeyMed/CSPC) is NMPA-approved across three indications.
The readout
MG-K10 (comekibart), a long-acting anti-IL-4Rα antibody developed by Mabgeek, just gave that pattern a headline. At the 2026 AAD Annual Meeting, Jianzhong Zhang, MD, PhD, of Peking University People’s Hospital presented 52-week Phase III data from 499 adults with moderate-to-severe atopic dermatitis, randomized 2:1 to MG-K10 (300 mg every four weeks, 600 mg loading dose) or placebo:
- EASI-75 (a 75% reduction in eczema severity): 59.8% on MG-K10 vs. 22.9% on placebo at week 16 (P<0.0001)
- IGA response (clinician-rated near-clearance): 32.7% vs. 7.2% at week 16 (P<0.0001)
- By week 52: 94.3% EASI-75 and 76.6% IGA response, durable through a full year, with mostly grade 1/2 adverse events
Dr. Zhang positioned the drug’s extended, once-monthly dosing as a differentiator versus other anti-IL-4Rα antibodies, which require biweekly injections.
Why this changes the calculus, not just the leaderboard
IL-4Rα blockade is mature enough that competitive intensity should be slowing down. Instead, a wave of Chinese fast-followers, plus one US biotech that routed through a Chinese partner to get there, is differentiating on dosing, durability, and cost. That cuts two ways:
- Looking to license or partner on IL-4Rα? The West’s late-stage bench on this target is close to empty outside what’s already licensed in. This group of ten, not the two or three Western names you can list, is the live field.
- Already compete on this mechanism, in AD, asthma, or CRSwNP? Your real comp set is this group, and MG-K10’s numbers are now part of the bar.
Why this is easy to miss
None of this shows up in a search built around a fixed list of familiar sponsors instead of the target itself. Assets like SHR-1819, QX005N, and QL2108 don’t carry household names, and even rademikibart’s China angle is easy to miss if you’re only tracking Connect Biopharma as a US respiratory company. A sponsor-first search catches the names you already know. It misses the other nine.
What running this in VibeOne got us
One search on IL-4Rα returned mechanism, sponsor, stage, and geography for every tracked asset, sourced back to primary filings and trial registries rather than aggregator summaries. That’s the gap VibeOne is built to close: one search, every asset, sourced to primary filings, instead of a sponsor-first search that only ever finds the names you already know to look for.
We’re tracking all ten programs behind this pattern. If you want to see what’s in development for IL-4R, reach out and we’ll walk you through the full landscape.